Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jul;63(7):755–758. doi: 10.1136/ard.2004.020719

TNFα therapy in psoriatic arthritis and psoriasis

P Mease
PMCID: PMC1755077  PMID: 15194567

Full Text

The Full Text of this article is available as a PDF (75.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoni Christian, Dechant Claudia, Hanns-Martin Lorenz P. D., Wendler Joerg, Ogilvie Alexandra, Lueftl Mathias, Kalden-Nemeth Dolores, Kalden Joachim R., Manger Bernhard. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506–512. doi: 10.1002/art.10671. [DOI] [PubMed] [Google Scholar]
  2. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  3. Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6;319(6053):516–518. doi: 10.1038/319516a0. [DOI] [PubMed] [Google Scholar]
  4. Biondi Oriente C., Scarpa R., Pucino A., Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989;146:69–71. [PubMed] [Google Scholar]
  5. Bonifati C., Carducci M., Cordiali Fei P., Trento E., Sacerdoti G., Fazio M., Ameglio F. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity. Clin Exp Dermatol. 1994 Sep;19(5):383–387. doi: 10.1111/j.1365-2230.1994.tb02687.x. [DOI] [PubMed] [Google Scholar]
  6. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  7. Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0. [DOI] [PubMed] [Google Scholar]
  8. Danning C. L., Illei G. G., Hitchon C., Greer M. R., Boumpas D. T., McInnes I. B. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000 Jun;43(6):1244–1256. doi: 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  9. Davis John C., Jr, Van Der Heijde Désirée, Braun Jurgen, Dougados Maxime, Cush John, Clegg Daniel O., Kivitz Alan, Fleischmann Roy, Inman Robert, Tsuji Wayne. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230–3236. doi: 10.1002/art.11325. [DOI] [PubMed] [Google Scholar]
  10. Dayer J. M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. doi: 10.1084/jem.162.6.2163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ettehadi P., Greaves M. W., Wallach D., Aderka D., Camp R. D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994 Apr;96(1):146–151. doi: 10.1111/j.1365-2249.1994.tb06244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fearon Ursula, Griosios Konstantina, Fraser Alexander, Reece Richard, Emery Paul, Jones Pamela F., Veale Douglas J. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003 Feb;30(2):260–268. [PubMed] [Google Scholar]
  13. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397. [DOI] [PubMed] [Google Scholar]
  14. Furst Daniel E., Schiff Michael H., Fleischmann Roy M., Strand Vibeke, Birbara Charles A., Compagnone Daniele, Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. [PubMed] [Google Scholar]
  15. Genovese Mark C., Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. doi: 10.1002/art.10308. [DOI] [PubMed] [Google Scholar]
  16. Gladman D. D., Shuckett R., Russell M. L., Thorne J. C., Schachter R. K. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med. 1987 Feb;62(238):127–141. [PubMed] [Google Scholar]
  17. Gladman D. D., Stafford-Brady F., Chang C. H., Lewandowski K., Russell M. L. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990 Jun;17(6):809–812. [PubMed] [Google Scholar]
  18. Goedkoop A. Y., Kraan M. C., Teunissen M. B. M., Picavet D. I., de Rie M. A., Bos J. D., Tak P. P. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis. 2004 Jul;63(7):769–773. doi: 10.1136/ard.2003.018085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  20. Gottlieb Alice B., Masud Salman, Ramamurthi Rallapalli, Abdulghani Ahsan, Romano Pat, Chaudhari Umesh, Dooley Lisa T., Fasanmade Adedigbo A., Wagner Carrie L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003 Jan;48(1):68–75. doi: 10.1067/mjd.2003.10. [DOI] [PubMed] [Google Scholar]
  21. Gottlieb Alice B., Matheson Robert T., Lowe Nicholas, Krueger Gerald G., Kang Sewon, Goffe Bernard S., Gaspari Anthony A., Ling Mark, Weinstein Gerald D., Nayak Anjuli. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec;139(12):1627–1632. doi: 10.1001/archderm.139.12.1627. [DOI] [PubMed] [Google Scholar]
  22. Hanauer Stephen B., Feagan Brian G., Lichtenstein Gary R., Mayer Lloyd F., Schreiber S., Colombel Jean Frederic, Rachmilewitz Daniel, Wolf Douglas C., Olson Allan, Bao Weihang. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4. [DOI] [PubMed] [Google Scholar]
  23. Husted J. A., Gladman D. D., Farewell V. T., Cook R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001 Apr;45(2):151–158. doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  24. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996 Jul;14(3):485–496. doi: 10.1016/s0733-8635(05)70376-4. [DOI] [PubMed] [Google Scholar]
  25. Krueger G., Koo J., Lebwohl M., Menter A., Stern R. S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar;137(3):280–284. [PubMed] [Google Scholar]
  26. Krueger James G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002 Jan;46(1):1–26. doi: 10.1067/mjd.2002.120568. [DOI] [PubMed] [Google Scholar]
  27. Laloux L., Voisin M. C., Allain J., Martin N., Kerboull L., Chevalier X., Claudepierre P. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001 Apr;60(4):316–321. doi: 10.1136/ard.60.4.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Leonardi Craig L., Powers Jerold L., Matheson Robert T., Goffe Bernard S., Zitnik Ralph, Wang Andrea, Gottlieb Alice B., Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. doi: 10.1056/NEJMoa030409. [DOI] [PubMed] [Google Scholar]
  29. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  30. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  31. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  32. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  33. Moll J. M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78. doi: 10.1016/0049-0172(73)90035-8. [DOI] [PubMed] [Google Scholar]
  34. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  35. Partsch G., Steiner G., Leeb B. F., Dunky A., Bröll H., Smolen J. S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997 Mar;24(3):518–523. [PubMed] [Google Scholar]
  36. Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Jr, Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x. [DOI] [PubMed] [Google Scholar]
  37. Reece R. J., Canete J. D., Parsons W. J., Emery P., Veale D. J. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999 Jul;42(7):1481–1484. doi: 10.1002/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  38. Ritchlin C., Haas-Smith S. A., Hicks D., Cappuccio J., Osterland C. K., Looney R. J. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998 Aug;25(8):1544–1552. [PubMed] [Google Scholar]
  39. Ritchlin Christopher T., Haas-Smith Sally A., Li Ping, Hicks David G., Schwarz Edward M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003 Mar;111(6):821–831. doi: 10.1172/JCI16069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986 Aug 7;322(6079):547–549. doi: 10.1038/322547a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Salvarani C., Lo Scocco G., Macchioni P., Cremonesi T., Rossi F., Mantovani W., Battistel B., Bisighini G., Portioli I. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol. 1995 Aug;22(8):1499–1503. [PubMed] [Google Scholar]
  42. Scarpa R., Oriente P., Pucino A., Torella M., Vignone L., Riccio A., Biondi Oriente C. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984 Nov;23(4):246–250. doi: 10.1093/rheumatology/23.4.246. [DOI] [PubMed] [Google Scholar]
  43. Shbeeb M., Uramoto K. M., Gibson L. E., O'Fallon W. M., Gabriel S. E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000 May;27(5):1247–1250. [PubMed] [Google Scholar]
  44. Shinmei M., Masuda K., Kikuchi T., Shimomura Y. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl. 1989 Aug;18:32–34. [PubMed] [Google Scholar]
  45. Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
  46. Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029–1035. doi: 10.1056/NEJM199710093371502. [DOI] [PubMed] [Google Scholar]
  47. Terajima S., Higaki M., Igarashi Y., Nogita T., Kawashima M. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res. 1998 May;290(5):246–252. doi: 10.1007/s004030050299. [DOI] [PubMed] [Google Scholar]
  48. Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993 Jul;36(7):893–900. doi: 10.1002/art.1780360705. [DOI] [PubMed] [Google Scholar]
  49. Victor Frank C., Gottlieb Alice B. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002 Dec;1(3):264–275. [PubMed] [Google Scholar]
  50. Wakefield P. E., James W. D., Samlaska C. P., Meltzer M. S. Tumor necrosis factor. J Am Acad Dermatol. 1991 May;24(5 Pt 1):675–685. doi: 10.1016/0190-9622(91)70102-8. [DOI] [PubMed] [Google Scholar]
  51. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  52. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  53. Winchester R., Brancato L., Itescu S., Skovron M. L., Solomon G. Implications from the occurrence of Reiter's syndrome and related disorders in association with advanced HIV infection. Scand J Rheumatol Suppl. 1988;74:89–93. doi: 10.3109/03009748809102943. [DOI] [PubMed] [Google Scholar]
  54. Wong K., Gladman D. D., Husted J., Long J. A., Farewell V. T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997 Oct;40(10):1868–1872. doi: 10.1002/art.1780401021. [DOI] [PubMed] [Google Scholar]
  55. van de Putte L. B. A., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L. C. M., Schattenkirchner M., Emery P., Burmester G. R., Zeidler H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003 Dec;62(12):1168–1177. doi: 10.1136/ard.2003.009563. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES